FR2466990A1 - Compositions synergiques pour stimuler l'activite phagocytaire, comprenant une solution contenant de la muramidase et un sel de l'acide hyaluronique - Google Patents
Compositions synergiques pour stimuler l'activite phagocytaire, comprenant une solution contenant de la muramidase et un sel de l'acide hyaluronique Download PDFInfo
- Publication number
- FR2466990A1 FR2466990A1 FR8021818A FR8021818A FR2466990A1 FR 2466990 A1 FR2466990 A1 FR 2466990A1 FR 8021818 A FR8021818 A FR 8021818A FR 8021818 A FR8021818 A FR 8021818A FR 2466990 A1 FR2466990 A1 FR 2466990A1
- Authority
- FR
- France
- Prior art keywords
- phagocytosis
- muas
- muramidase
- stimulating
- activity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010014251 Muramidase Proteins 0.000 title claims abstract description 56
- 102000016943 Muramidase Human genes 0.000 title claims abstract description 56
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 title claims abstract description 56
- 235000010335 lysozyme Nutrition 0.000 title claims abstract description 54
- 229940051921 muramidase Drugs 0.000 title claims abstract description 50
- 239000000203 mixture Substances 0.000 title claims abstract description 16
- 230000004936 stimulating effect Effects 0.000 title claims abstract description 12
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 title claims abstract description 11
- 229920002674 hyaluronan Polymers 0.000 title claims abstract description 11
- 229960003160 hyaluronic acid Drugs 0.000 title claims abstract description 11
- 150000003839 salts Chemical class 0.000 title claims abstract description 6
- 230000000694 effects Effects 0.000 title description 22
- 230000002195 synergetic effect Effects 0.000 title description 3
- 210000004369 blood Anatomy 0.000 claims abstract description 11
- 239000008280 blood Substances 0.000 claims abstract description 11
- 241000124008 Mammalia Species 0.000 claims abstract 3
- 150000001875 compounds Chemical class 0.000 claims abstract 3
- 206010057249 Phagocytosis Diseases 0.000 claims description 49
- 230000008782 phagocytosis Effects 0.000 claims description 49
- 239000000243 solution Substances 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 239000002504 physiological saline solution Substances 0.000 claims description 2
- 239000012266 salt solution Substances 0.000 claims 1
- 230000000242 pagocytic effect Effects 0.000 abstract description 12
- 238000000034 method Methods 0.000 abstract description 9
- 210000004027 cell Anatomy 0.000 description 33
- 230000000638 stimulation Effects 0.000 description 18
- 239000002245 particle Substances 0.000 description 16
- 230000037406 food intake Effects 0.000 description 15
- 210000001539 phagocyte Anatomy 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 230000005764 inhibitory process Effects 0.000 description 9
- 210000000265 leukocyte Anatomy 0.000 description 7
- 210000003622 mature neutrocyte Anatomy 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 6
- 239000011324 bead Substances 0.000 description 5
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 4
- 102000002322 Egg Proteins Human genes 0.000 description 4
- 108010000912 Egg Proteins Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 235000014103 egg white Nutrition 0.000 description 4
- 210000000969 egg white Anatomy 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 229960000274 lysozyme Drugs 0.000 description 4
- 239000004325 lysozyme Substances 0.000 description 4
- 210000002864 mononuclear phagocyte Anatomy 0.000 description 4
- 239000011049 pearl Substances 0.000 description 4
- 210000003024 peritoneal macrophage Anatomy 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- 229920003023 plastic Polymers 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 159000000000 sodium salts Chemical class 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 108700022034 Opsonin Proteins Proteins 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 229940014041 hyaluronate Drugs 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000004816 latex Substances 0.000 description 3
- 229920000126 latex Polymers 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 230000015323 positive regulation of phagocytosis Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241000312117 Phago Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 230000003095 anti-phagocytic effect Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 229920002113 octoxynol Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 210000001179 synovial fluid Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241001331845 Equus asinus x caballus Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001018100 Homo sapiens Lysozyme C Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- HZFDKBPTVOENNB-GAFUQQFSSA-N N-[(2S)-1-[2-[(2R)-2-chloro-2-fluoroacetyl]-2-[[(3S)-2-oxopyrrolidin-3-yl]methyl]hydrazinyl]-3-(1-methylcyclopropyl)-1-oxopropan-2-yl]-5-(difluoromethyl)-1,2-oxazole-3-carboxamide Chemical compound CC1(C[C@@H](C(NN(C[C@H](CCN2)C2=O)C([C@H](F)Cl)=O)=O)NC(C2=NOC(C(F)F)=C2)=O)CC1 HZFDKBPTVOENNB-GAFUQQFSSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 241001505901 Streptococcus sp. 'group A' Species 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000009830 antibody antigen interaction Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000002999 depolarising effect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 210000000224 granular leucocyte Anatomy 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 229940089982 healon Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- NAFSTSRULRIERK-UHFFFAOYSA-M monosodium urate Chemical class [Na+].N1C([O-])=NC(=O)C2=C1NC(=O)N2 NAFSTSRULRIERK-UHFFFAOYSA-M 0.000 description 1
- 230000015286 negative regulation of phagocytosis Effects 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000003114 pinocytic effect Effects 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 238000011158 quantitative evaluation Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000015736 regulation of phagocytosis Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 210000000506 subperitoneum Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- CWERGRDVMFNCDR-UHFFFAOYSA-M thioglycolate(1-) Chemical compound [O-]C(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-M 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/084,615 US4272522A (en) | 1979-10-15 | 1979-10-15 | Method for stimulating phagocytic activity and synergistic compositions therefor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2466990A1 true FR2466990A1 (fr) | 1981-04-17 |
| FR2466990B1 FR2466990B1 (enExample) | 1984-07-27 |
Family
ID=22186108
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR8021818A Granted FR2466990A1 (fr) | 1979-10-15 | 1980-10-13 | Compositions synergiques pour stimuler l'activite phagocytaire, comprenant une solution contenant de la muramidase et un sel de l'acide hyaluronique |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US4272522A (enExample) |
| JP (1) | JPS5663921A (enExample) |
| CA (1) | CA1151541A (enExample) |
| FR (1) | FR2466990A1 (enExample) |
| GB (1) | GB2060380B (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1229075B (it) * | 1985-04-05 | 1991-07-17 | Fidia Farmaceutici | Medicamenti per uso topico, ottenuti tramite l'impiego dell'acido ialuronico |
| IT1212892B (it) * | 1983-10-11 | 1989-11-30 | Della Valle Francesco | Acido ialuronico ottenuto per mezzodi filtrazione molecolare sprovvisto di attivita' infiammatoria e sua utilizzazione terapeutica |
| US5166331A (en) * | 1983-10-10 | 1992-11-24 | Fidia, S.P.A. | Hyaluronics acid fractions, methods for the preparation thereof, and pharmaceutical compositions containing same |
| JPS5995221A (ja) * | 1982-11-20 | 1984-06-01 | Mochida Pharmaceut Co Ltd | 食細胞機能調節作用を有する医薬組成物 |
| US4500676A (en) * | 1983-12-15 | 1985-02-19 | Biomatrix, Inc. | Hyaluronate modified polymeric articles |
| US4487865A (en) * | 1983-12-15 | 1984-12-11 | Biomatrix, Inc. | Polymeric articles modified with hyaluronate |
| JPS6147418A (ja) * | 1984-08-13 | 1986-03-07 | Seikagaku Kogyo Co Ltd | ヒアルロン酸含有胃粘膜保護剤 |
| US4801475A (en) * | 1984-08-23 | 1989-01-31 | Gregory Halpern | Method of hydrophilic coating of plastics |
| US4713448A (en) * | 1985-03-12 | 1987-12-15 | Biomatrix, Inc. | Chemically modified hyaluronic acid preparation and method of recovery thereof from animal tissues |
| US5099013A (en) * | 1985-03-12 | 1992-03-24 | Biomatrix, Inc, | Hylan preparation and method of recovery thereof from animal tissues |
| US4663233A (en) * | 1985-10-24 | 1987-05-05 | Universal High Technologies | Lens with hydrophilic coating |
| DE3684887D1 (de) * | 1985-11-29 | 1992-05-21 | Biomatrix Inc | Arzneistoffabgabesysteme auf basis von hyaluronan, dessen derivaten und salzen sowie verfahren zu deren herstellung. |
| US4808576A (en) * | 1986-04-28 | 1989-02-28 | Mobay Corporation | Remote administration of hyaluronic acid to mammals |
| CA1340994C (en) * | 1989-09-21 | 2000-05-16 | Rudolf Edgar Dr. Falk | Treatment of conditions and disease |
| US5102783A (en) * | 1990-01-12 | 1992-04-07 | Vetrepharm, Inc. | Composition and method for culturing and freezing cells and tissues |
| CA2061703C (en) * | 1992-02-20 | 2002-07-02 | Rudolf E. Falk | Formulations containing hyaluronic acid |
| US5639738A (en) * | 1992-02-20 | 1997-06-17 | Hyal Pharmaceutical Corporation | Treatment of basal cell carcinoma and actinic keratosis employing hyaluronic acid and NSAIDs |
| US5910489A (en) * | 1990-09-18 | 1999-06-08 | Hyal Pharmaceutical Corporation | Topical composition containing hyaluronic acid and NSAIDS |
| US5990096A (en) * | 1990-09-18 | 1999-11-23 | Hyal Pharmaceutical Corporation | Formulations containing hyaluronic acid |
| US5824658A (en) * | 1990-09-18 | 1998-10-20 | Hyal Pharmaceutical Corporation | Topical composition containing hyaluronic acid and NSAIDS |
| US5990095A (en) * | 1991-07-03 | 1999-11-23 | Hyal Pharmaceutical Corporation | Use of hyaluronic acid and forms to prevent arterial restenosis |
| WO1994007505A1 (en) * | 1991-07-03 | 1994-04-14 | Norpharmco Inc. | Use of hyaluronic acid and forms to prevent arterial restenosis |
| US5817644A (en) * | 1991-07-03 | 1998-10-06 | Hyal Pharmaceutical Corporation | Targeting of dosages of medicine and therapeutic agents |
| US5977088A (en) * | 1991-07-03 | 1999-11-02 | Hyal Pharmaceutical Corporation | Formulations containing hyaluronic acid |
| US6022866A (en) * | 1991-07-03 | 2000-02-08 | Hyal Pharmaceutical Corporation | Use of hyaluronic acid and forms to prevent arterial restenosis |
| US5792753A (en) * | 1991-07-03 | 1998-08-11 | Hyal Pharmaceutical Corporation | Compositions comprising hyaluronic acid and prostaglandin-synthesis-inhibiting drugs |
| US6103704A (en) * | 1991-07-03 | 2000-08-15 | Hyal Pharmaceutical Corporation | Therapeutic methods using hyaluronic acid |
| US6147059A (en) * | 1992-02-20 | 2000-11-14 | Hyal Pharmaceutical Corporation | Formulations containing hyaluronic acid |
| US6218373B1 (en) | 1992-02-20 | 2001-04-17 | Hyal Pharmaceutical Corporation | Formulations containing hyaluronic acid |
| US5767106A (en) * | 1992-02-21 | 1998-06-16 | Hyal Pharmaceutical Corporation | Treatment of disease and conditions associated with macrophage infiltration |
| JP4818608B2 (ja) * | 2002-07-03 | 2011-11-16 | ペリコール・サイエンス・インコーポレーテッド | ヒアルロン酸の組成物および使用方法 |
| AU2007295894B2 (en) * | 2006-09-13 | 2013-10-17 | Enhance Skin Products, Inc. | Cosmetic composition for the treatment of skin and methods thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4141973A (en) * | 1975-10-17 | 1979-02-27 | Biotrics, Inc. | Ultrapure hyaluronic acid and the use thereof |
-
1979
- 1979-10-15 US US06/084,615 patent/US4272522A/en not_active Expired - Lifetime
-
1980
- 1980-10-08 CA CA000361813A patent/CA1151541A/en not_active Expired
- 1980-10-10 GB GB8032722A patent/GB2060380B/en not_active Expired
- 1980-10-13 FR FR8021818A patent/FR2466990A1/fr active Granted
- 1980-10-13 JP JP14214880A patent/JPS5663921A/ja active Granted
Non-Patent Citations (3)
| Title |
|---|
| CHEMICAL ABSTRACTS, vol. 82, no. 1, 6 janvier 1975, page 221, no. 2373r, Columbus Ohio (USA); * |
| CHEMICAL ABSTRACTS, vol. 83, no. 2, 14 juillet 1975, page 210, no. 128091m, Columbus Ohio (USA); * |
| CHEMICAL ABSTRACTS, vol. 84, no. 19, 10 mai 1976, page 321, no. 133551m, Columbus Ohio (USA); * |
Also Published As
| Publication number | Publication date |
|---|---|
| CA1151541A (en) | 1983-08-09 |
| JPS636048B2 (enExample) | 1988-02-08 |
| FR2466990B1 (enExample) | 1984-07-27 |
| US4272522A (en) | 1981-06-09 |
| GB2060380A (en) | 1981-05-07 |
| GB2060380B (en) | 1983-08-10 |
| JPS5663921A (en) | 1981-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR2466990A1 (fr) | Compositions synergiques pour stimuler l'activite phagocytaire, comprenant une solution contenant de la muramidase et un sel de l'acide hyaluronique | |
| Tauber et al. | Chronic granulomatous disease: a syndrome of phagocyte oxidase deficiencies | |
| Ohno et al. | Subcellular localization of H2O2 production in human neutrophils stimulated with particles and an effect of cytochalasin-B on the cells | |
| JPH07507550A (ja) | 非繊維形成誘導性アルギン酸被覆移植体，その製造方法およびその使用方法 | |
| McConnell et al. | Studies on the electron transfer system: LXV. Formation of membranes by purified cytochrome oxidase | |
| DK165221B (da) | Belagte transplantater og fremgangsmaade til belaegning af disse | |
| WO2008127567A1 (en) | Novel nutritional food products for improved digestion and intestinal absorption | |
| JP5409710B2 (ja) | 心肺バイパス（ｃｐｂ）手術の術後合併症を低減するための組成物 | |
| WO2012004522A1 (fr) | Complexe macromoleculaire d'origine bacterienne et utilisation dudit complexe macromoleculaire pour prevenir et traiter les rhumatismes inflammatoires | |
| JPS5816693A (ja) | 細胞により産生される物質の製造方法 | |
| EP3291905B1 (fr) | Support pour la purification de liquides biologiques | |
| CN114306581A (zh) | 一种融合细胞膜包裹尿酸酶/过氧化氢酶脂质纳米粒及其制备方法 | |
| JP2004262777A (ja) | アセチル化ヒアルロン酸含有眼用医薬組成物 | |
| JPS63146833A (ja) | 後生的なグリコシル化最終産物を除去する為の方法及び薬剤 | |
| Egberts et al. | Biological and pathobiological aspects of the glycocalyx of the small intestinal epithelium. A review | |
| Eizirik et al. | Predominance of stimulatory effects of interleukin-1 beta on isolated human pancreatic islets | |
| CN120392949B (zh) | 一种口腔黏膜的修复药物及其制备方法 | |
| FR2940087A1 (fr) | Erythrocytes contenant du facteur viii, preparation et utilisations. | |
| Nøorgaard et al. | Neutrophil degranulation by Helicobacter pylori proteins. | |
| JPH11512437A (ja) | Ｓ−ニトロソチオールを負荷した赤血球およびその使用 | |
| US5395612A (en) | Method for treating systemic hypotension caused by sepsis or cytokine using arginase in combination with an α1 adrenergic agonist | |
| Blau et al. | Studies on human milk macrophages: effect of activation on phagocytosis and secretion of prostaglandin E2 and lysozyme | |
| JPS6136221A (ja) | 免疫抑制剤としてのリコリンの使用 | |
| AU2022328354A1 (en) | Methods and compositions for treating fructose intolerance and fructose malabsorption | |
| Tietze et al. | Enzymic Reduction of Cystine by Subcellular Fractions of Cultured and Peripheral Leukoyctes from Normal and Cystinotic Individuals |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| TP | Transmission of property |